comparemela.com
Home
Live Updates
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009 : comparemela.com
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
/PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel,...
Related Keywords
Tennessee ,
United States ,
University School ,
Amanda Wagner ,
James Wooldridge ,
Aeglea Biotherapeutics ,
Melissal Johnson ,
Eli Lilly ,
University Of Missouri ,
University Of Iowa ,
Tulane University School Of Medicine ,
Checkmate Pharmaceuticals ,
Clinical Development ,
Clinical Advisory Board ,
Immunitas Therapeutics ,
Clinical Advisory ,
Lung Cancer Research ,
Sarah Cannon Research Institute ,
Tennessee Oncology ,
Study Chair ,
Principal Investigator ,
Recommended Phase ,
Chief Executive Officer ,
Chief Medical Officer ,
Chief Scientific Officer ,
Immuno Oncology Clinical ,
Tulane University School ,
Fc Attenuated Igg ,
Nc ,
comparemela.com © 2020. All Rights Reserved.